Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular classification^[1-3]

ProMisE algorithm. It is anticipated that all molecular tests will be performed on diagnostic biopsies or hysterectomy specimens of newly diagnosed ECs. Order of classification begins with first pulling out ECs with pathogenic POLE mutations,^[1] next identifying patients with mismatch repair deficiency (loss of MMR proteins on IHC), and finally identifying patients with aberrant versus wild-type p53 IHC staining.^[2] Approximately 3% of ECs have more than one molecular classifying feature ("multiple-classifier" ECs) with the shown order of segregation appropriately defining their predominant tumor biology and clinical behavior.^[3]